Home
  >  
Section 4
  >  
Chapter 3,074

Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice

Connolly, P.; Wheat, J.; Schnizlein-Bick, C.; Durkin, M.; Kohler, S.; Smedema, M.; Goldberg, J.; Brizendine, E.; Loebenberg, D.

Antimicrobial Agents and ChemoTherapy 43(2): 322-328

1999


ISSN/ISBN: 0066-4804
PMID: 9925526
Accession: 003073894

Download citation:  
Text
  |  
BibTeX
  |  
RIS

A murine model of intratracheally induced Histoplasma capsulatum infection was used to evaluate Schering (SCH) 56592 for treatment of histoplasmosis. Minimum inhibitory concentrations (MICs) were determined for SCH 56592, amphotericin B and itraconazole by testing yeast-phase isolates from 20 patients by a macrobroth dilution method.

PDF emailed within 1 workday: $29.90